Skip to main content
. 2021 Oct 17;41(8):1915–1935. doi: 10.1007/s10875-021-01141-0

Fig. 2.

Fig. 2

ADA2 mutations impede B cell development in the bone marrow at the preB to immature B cell stage. A, B BM aspirates from healthy donors, or a DADA2 patient were labeled with mAbs against CD34, CD19, CD20, CD10, IgM and IgD. A Proportions of B-lineage cells (CD19+), pro-B (CD19+CD34+CD10hi), pre-BI (CD19+CD34CD10hi), pre-BII (CD19+CD34CD10hi), immature (CD19+CD34CD10int) and recirculating mature (CD19+CD34CD10CD20+) B cells. B Each BM B cell subset in healthy donors (black histogram) and DADA2 patients (red histogram) was assessed for expression of IgM (upper) and IgD (lower panel). Values in B correspond to the gMFI of IgM and IgD expression on BM B cell subsets from in healthy donors (black) and the DADA2 patient (red)